Dabrafenib and Trametinib for Non-Small Cell Lung Cancer BRAF V600 Mutation

Details

Files
Generic Name:
Dabrafenib and Trametinib
Project Status:
Complete
Therapeutic Area:
NSCLC BRAF V600
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Tafinlar and Mekinist
Project Line:
Reimbursement Review
Project Number:
PC0226-000
NOC Status at Filing:
Post NOC
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer (NSCLC) BRAF V600 mutation
Funding Request:
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have not received any prior anti-cancer therapy for metastatic disease.
Review Status:
Notification to Implement Issued
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation:

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.